SCYX
SCYNEXIS, Inc.
1.74
USD
This page is just a preview of the data found in TrendSpider’s full version
SCYNEXIS, Inc. stock is up 1.75% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 9 December’s closed higher than November.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm, CJSC.
